Our AML flow cytometry based assay is designed for testing readily available peripheral blood or bone marrow biopsy samples, which are typically obtained during patient diagnosis. Individual tests for several treatment options have been developed and validated in our CLIA-certified laboratory. Larger scale verification studies are underway with pharma and academic collaborators.
For CLL patient samples, a second version of the assay is used for testing patient samples. Initial clinical studies have identified new predictive biomarker algorithms that predict patient response to those treatments and that forecast on onset of certain adverse events in those patients. Larger verification studies are underway with pharma and academic collaborators to support reimbursement.